natgillin/translations-raw huggingface dataset:
Processed cereal-based food and baby food for infants and young children as defined in Directive 2006/125/EC
Žitne kašice ter hrana za dojenčke in majhne otroke, kot so opredeljene v Direktivi 2006/125/ES
0,6 g/l for liquid food ready for use, marketed as such or reconstituted as instructed by the manufacturer
0,6 g/l za tekoča živila, ki so pripravljena za uporabo in se kot taka tržijo ali se pripravijo po navodilu proizvajalca
0,6 g/l for milk-based drinks and similar products added alone or in combination with 2′-O-fucosyllactose, at concentrations 1,2 g/l, at a ratio of 1:2 in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer
0,6 g/l za mlečne napitke in podobne proizvode, pri čemer je navedena snov dodana posamično ali v kombinaciji z 2′-O-fukozillaktozo v koncentraciji 1,2 g/l in v razmerju 1: 2 v končnem proizvodu, ki je pripravljen za uporabo in se kot tak trži ali se pripravi po navodilu proizvajalca
Foods intended for use in energy-restricted diets for weight reduction as defined in Directive 96/8/EC (only for products presented as a replacement for the whole of the daily diet)
Živila, namenjena za uporabo pri energijsko omejenih dietah za zmanjšanje telesne teže, kot so opredeljena v Direktivi 96/8/ES (samo za proizvode, ki so predstavljeni kot nadomestilo za celotno dnevno zaužito hrano)
2,4 g/l for drinks
2,4 g/l za pijače
20 g/kg for bars
20 g/kg za ploščice
Bread and pasta products for people intolerant to gluten as defined in Regulation (EC) No 41/2009 [1]
Kruh in testenine, primerni za ljudi s preobčutljivostjo na gluten, kot so opredeljeni v Uredbi (ES) št. 41/2009 [1]
Coffee, tea (excluding black tea), herbal and fruit infusions, chicory; tea, herbal and fruit infusions and chicory extracts; tea, plant, fruit and cereal preparations for infusions, as well as mixes and instant mixes of these products
Kava, pravi čaj (razen črnega čaja), zeliščni in sadni poparki, cikorija; čaj, zeliščni in sadni poparki ter izvlečki cikorije; čajni, rastlinski in sadni pripravki in žitni pripravki za poparke ter mešanice in instant mešanice teh proizvodov
Food supplements as defined in Directive 2002/46/EC, excluding food supplements for infants
Prehranska dopolnila, kot so opredeljena v Direktivi 2002/46/ES, razen prehranskih dopolnil za dojenčke
1,5 g/day for general population
1,5 g/dan za splošno populacijo
0,6 g/day for young children
0,6 g/dan za majhne otroke
From 20 July 2016 the category ‘Bread and pasta products for people intolerant to gluten as defined in Regulation (EC) No 41/2009’ shall be replaced by the following: ‘Bread and pasta products bearing statements on the absence or reduced presence of gluten in accordance with the requirements of Commission Implementing Regulation (EU) No 828/2014’.
Od 20. julija 2016 bo kategorija „Kruh in testenine, primerni za ljudi s preobčutljivostjo na gluten, kot so opredeljeni v Uredbi (ES) št. 41/2009“ nadomeščena z naslednjo: „Kruh in testenine, na katerih so navedene izjave o odsotnosti ali zmanjšani prisotnosti glutena v skladu z zahtevami Izvedbene uredbe Komisije (EU) št. 828/2014“.
The maximum level refers to the products ready to use.
Mejne vrednosti veljajo za proizvode, pripravljene za uporabo.
Commission Implementing Decision (EU) 2016/376
Izvedbeni sklep Komisije (EU) 2016/376
authorising the placing on the market of 2′-O-fucosyllactose as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council
o odobritvi dajanja na trg 2′-O-fukozillaktoze kot nove živilske sestavine v skladu z Uredbo (ES) št. 258/97 Evropskega parlamenta in Sveta
(notified under document C(2016) 1423)
(notificirano pod dokumentarno številko C(2016) 1423)
On 23 June 2014, the company Glycom A/S made a request to the competent authorities of Ireland to place 2′-O-fucosyllactose on the market as a novel food ingredient.
Podjetje Glycom A/S je 23. junija 2014 vložilo zahtevek pri pristojnih organih Irske za dajanje na trg 2′-O-fukozillaktoze kot nove živilske sestavine.
On 3 October 2014, the competent food assessment body of Ireland issued its initial assessment report.
Pristojni organ Irske za presojo živil je 3. oktobra 2014 izdal poročilo o začetni presoji.
In that report, it came to the conclusion that 2′-O-fucosyllactose meets the criteria for novel food set out in Article 3(1) of Regulation (EC) No 258/97.
V navedenem poročilu ugotavlja, da 2′-O-fukozillaktoza izpolnjuje merila za novo živilo, določena v členu 3(1) Uredbe (ES) št. 258/97.
On 9 October 2014, the Commission forwarded the initial assessment report to the other Member States.
Komisija je 9. oktobra 2014 poročilo o začetni presoji poslala drugim državam članicam.
On 22 December 2014, the Commission consulted the European Food Safety Authority (EFSA) asking it to carry out an assessment for 2′-O-fucosyllactose as a novel food ingredient in accordance with Regulation (EC) No 258/97.
Komisija se je 22. decembra 2014 posvetovala z Evropsko agencijo za varnost hrane (v nadaljnjem besedilu: EFSA) in jo prosila za oceno 2′-O-fukozillaktoze kot nove živilske sestavine v skladu z Uredbo (ES) št. 258/97.
On 29 June 2015, EFSA in its ‘Scientific Opinion on the safety of 2′-O-fucosyllactose as a novel food ingredient pursuant to Regulation (EC) No 258/97’ [2], concluded that 2′-O-fucosyllactose is safe for the proposed uses and use levels.
EFSA je 29. junija 2015 v svojem znanstvenem mnenju o varnosti 2′-O-fukozillaktoze kot nove živilske sestavine v skladu z Uredbo (ES) št. 258/97 [2] ugotovila, da je 2′-O-fukozillaktoza varna ob predlaganih načinih uporabe in ravneh uporabe.
On 28 October 2015, EFSA in its ‘Statement on the safety of lacto-N-neotetraose and 2′-O-fucosyllactose as novel food ingredients in food supplements for children’ [3], concluded that 2′-O-fucosyllactose is safe for the proposed uses and use levels.
EFSA je 28. oktobra 2015 v svoji izjavi o varnosti lakto-N-neotetraoze in 2′-O-fukozillaktoze kot novih živilskih sestavin v prehranskih dopolnilih za otroke [3] ugotovila, da je 2′-O-fukozillaktoza varna ob predlaganih načinih uporabe in ravneh uporabe.
The use of 2′-O-fucosyllactose should be authorised without prejudice to the requirements of those legislations
Uporabo 2′-O-fukozillaktoze bi bilo treba odobriti brez poseganja v zahteve navedenih pravnih aktov.
2′-O-Fucosyllactose as specified in Annex I may be placed on the market in the Union as a novel food ingredient for the uses defined and at the maximum levels established in Annex II without prejudice to the specific provisions of Directives 96/8/EC, 1999/21/EC, 2002/46/EC, 2006/125/EC, 2006/141/EC and Regulations (EC) No 1925/2006, (EC) No 41/2009 and Implementing Regulation (EU) No 828/2014
2′-O-fukozillaktoza, kot je opredeljena v Prilogi I, se lahko da na trg Unije kot nova živilska sestavina za opredeljene načine uporabe in ob upoštevanju največjih dovoljenih vrednosti, ki so določene v Prilogi II, brez poseganja v posebne določbe direktiv 96/8/ES, 1999/21/ES, 2002/46/ES, 2006/125/ES in 2006/141/ES ter uredb (ES) št. 1925/2006, (ES) št. 41/2009 in Izvedbeno uredbo (EU) št. 828/2014.
The designation of 2′-O-fucosyllactose authorised by this Decision on the labelling of the foodstuffs containing it shall be ‘2′-O-fucosyllactose’.
Poimenovanje 2′-O-fukozillaktoze, odobrene s tem sklepom, na oznakah živil, ki jo vsebujejo, je „2′-O-fukozillaktoza“.
Information shall be given to the consumer that food supplements containing 2′-O-fucosyllactose should not be used if other foods with added 2′-O-fucosyllactose are consumed the same day.
Potrošnike se obvesti, da prehranskih dopolnil, ki vsebujejo 2′-O-fukozillaktozo, ne bi smeli uporabljati, če isti dan zaužijejo druga živila z dodano 2′-O-fukozillaktozo.
Information shall be given to the consumer that food supplements containing 2′-O-fucosyllactose intended for young children should not be used if breast milk or other foods with added 2′-O-fucosyllactose are consumed the same day.
Potrošnike se obvesti, da se prehranska dopolnila, ki vsebujejo 2′-O-fukozillaktozo in so namenjena otrokom, ne bi smela uporabiti, če otroci isti dan zaužijejo materino mleko ali druga živila z dodano 2′-O-fukozillaktozo.
EFSA Journal 2015; 13(7):4184.
EFSA Journal (2015);13(7):4184.
α-l-Fucopyranosyl-(1→2)-β-d-galactopyranosyl-(1→4)-d-glucopyranose
α-L-fukopiranozil-(1→2)-β-D-galaktopiranozil-(1→4)-D-glukopiranoza
Description: 2′-O-fucosyllactose is a white to off-white powder.
CAS
Purity:
Opis: 2′-O-fukozillaktoza je bel do umazano bel prah.
Not less than 95 %
Največ 95 %
Difucosyl-d-lactose isomers
Izomeri difukozil-D-laktoze
2′-Fucosyl-d-lactulose
2′-fukozil-D-laktuloza
pH (20 °C, 5 % solution)
pH (20 °C, 5 % raztopina)
AUTHORISED USES OF 2′-O-FUCOSYLLACTOSE
ODOBRENE UPORABE 2′-O-FUKOZILLAKTOZE
1,2 g/l beverages
1,2 g/l pijače
19,2 g/kg products other than beverages
19,2 g/kg proizvodov z izjemo pijač
12 g/kg for products other than beverages
12 g/kg za proizvode z izjemo pijač
400 g/kg for whitener
400 g/kg za mlečne nadomestke
1,2 g/l in combination with 0,6 g/l of lacto-N-neotetraose at a ratio of 2:1 in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer
1,2 g/l v kombinaciji z 0,6 g/l lakto-N-neotetraoze v razmerju 2: 1 v končnem proizvodu, ki je pripravljen za uporabo in se kot tak trži ali se pripravi po navodilu proizvajalca
1,2 g/l for liquid food ready for use, marketed as such or reconstituted as instructed by the manufacturer
1,2 g/l za tekoča živila, ki so pripravljena za uporabo in se kot taka tržijo ali se pripravijo po navodilu proizvajalca
1,2 g/l for milk-based drinks and similar products added alone or in combination with lacto-N-neotetraose, at concentrations 0,6 g/l, at a ratio of 2:1 in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer
1,2 g/l za mlečne napitke in podobne proizvode, pri čemer je navedena snov dodana posamično ali v kombinaciji z lakto-N-neotetraozo v koncentraciji 0,6 g/l in v razmerju 2: 1 v končnem proizvodu, ki je pripravljen za uporabo in se kot tak trži ali se pripravi po navodilu proizvajalca
4,8 g/l for drinks
4,8 g/l za pijače
40 g/kg for bars
40 g/kg za ploščice
Bread and pasta products for people intolerant to gluten as defined in Regulation (EC) No 41/2009 [1]
Kruh in testenine, primerni za ljudi s preobčutljivostjo na gluten, kot so opredeljeni v Uredbi (ES) št. 41/2009 [1]
3,0 g/day for general population
3,0 g/dan za splošno populacijo
1,2 g/day for young children
1,2 g/dan za majhne otroke
From 20 July 2016 the category ‘Bread and pasta products for people intolerant to gluten as defined in Regulation (EC) No 41/2009’ shall be replaced by the following: ‘Bread and pasta products bearing statements on the absence or reduced presence of gluten in accordance with the requirements of Commission Implementing Regulation (EU) No 828/2014’.
Od 20. julija 2016 bo kategorija „Kruh in testenine, primerni za ljudi s preobčutljivostjo na gluten, kot so opredeljeni v Uredbi (ES) št. 41/2009“ nadomeščena z naslednjo: „Kruh in testenine, na katerih so navedene izjave o odsotnosti ali zmanjšani prisotnosti glutena v skladu z zahtevami Izvedbene uredbe Komisije (EU) št. 828/2014“.
Commission Implementing Decision (EU) 2016/377
Izvedbeni sklep Komisije (EU) 2016/377
of 15 March 2016
z dne 15. marca 2016
on the equivalence of the regulatory framework of the United States of America for central counterparties that are authorised and supervised by the Commodity Futures Trading Commission to the requirements of Regulation (EU) No 648/2012 of the European Parliament and of the Council
o enakovrednosti regulativnega okvira Združenih držav Amerike za centralne nasprotne stranke, ki imajo dovoljenje Komisije za trgovanje z blagovnimi terminskimi pogodbami in so pod njenim nadzorom, zahtevam Uredbe (EU) št. 648/2012 Evropskega parlamenta in Sveta
Having regard to Regulation (EU) No 648/2012 of the European Parliament and of the Council of 4 July 2012 on OTC derivatives, central counterparties and trade repositories [1], and in particular Article 25(6) thereof,
ob upoštevanju Uredbe (EU) št. 648/2012 Evropskega parlamenta in Sveta z dne 4. julija 2012 o izvedenih finančnih instrumentih OTC, centralnih nasprotnih strankah in repozitorijih sklenjenih poslov [1], in zlasti člena 25(6) Uredbe,
That recognition procedure and the equivalence decision provided for therein thus contribute to the achievement of the overarching aim of Regulation (EU) No 648/2012 to reduce systemic risk by extending the use of safe and sound CCPs to clear over-the-counter (‘OTC’) derivative contracts, including where those CCPs are established and authorised in a third country.
Postopek priznanja in v tem okviru predvidena odločitev o enakovrednosti tako prispevata k doseganju poglavitnega cilja Uredbe (EU) št. 648/2012, tj. zmanjšanju sistemskega tveganja z razširjanjem uporabe varnih in stabilnih CNS za kliring pogodb o izvedenih finančnih instrumentih, s katerimi se trguje na prostem trgu (v nadaljnjem besedilu: izvedeni finančni instrumenti OTC), vključno s primeri, kadar imajo navedene CNS sedež in dovoljenje v tretji državi.
In order for a third country legal regime to be considered equivalent to the legal regime of the Union in respect of CCPs, the substantive outcome of the applicable legal and supervisory arrangements should be equivalent to Union requirements in respect of the regulatory objectives they achieve.
Da bi se pravne ureditve tretjih držav v zvezi s CNS obravnavale kot enakovredne pravni ureditvi Unije, bi morale biti veljavne pravne in nadzorne ureditve v smislu doseganja regulativnih ciljev v veliki meri enakovredne zahtevam Unije.
The purpose of this equivalence assessment is therefore to verify that the legal and supervisory arrangements of the United States of America (USA) ensure that CCPs established and authorised therein do not expose clearing members and trading venues established in the Union to a higher level of risk than the latter could be exposed to by CCPs authorised in the Union and, consequently, do not pose unacceptable levels of systemic risk in the Union.
Namen te ocene enakovrednosti je torej preveriti, ali pravne in nadzorne ureditve Združenih držav Amerike (ZDA) omogočajo, da CNS s sedežem in dovoljenjem v tej državi klirinških članov ali mest trgovanja s sedežem v Uniji ne izpostavljajo višji stopnji tveganja kot CNS z dovoljenjem v Uniji, posledično pa ne pomenijo nesprejemljivih stopenj sistemskega tveganja v Uniji.
On 1 September 2013, the Commission received the technical advice of the European Securities and Markets Authority (ESMA) on the legal and supervisory arrangements applicable to CCPs established in the USA.
Komisija je 1. septembra 2013 prejela strokovno mnenje Evropskega organa za vrednostne papirje in trge (v nadaljnjem besedilu: ESMA) glede pravnih in nadzornih ureditev, ki se uporabljajo za CNS s sedežem v ZDA.
That technical advice identified a number of differences between the legally binding requirements applicable, at jurisdictional level, to CCPs in the USA and the legally binding requirements applicable to CCPs under Regulation (EU) No 648/2012.
V strokovnem mnenju je bilo opredeljenih veliko razlik med pravno zavezujočimi zahtevami, ki na nacionalni ravni veljajo za CNS v ZDA, in pravno zavezujočimi zahtevami, ki se za CNS uporabljajo v skladu z Uredbo (EU) št. 648/2012.
This Decision is not only based, however, on a comparative analysis of the legally binding requirements applicable to CCPs in the USA, but also on an assessment of the outcome of those requirements, and their adequacy to mitigate the risks that clearing members and trading venues established in the Union may be exposed to in a manner considered equivalent to the outcome of the requirements laid down in Regulation (EU) No 648/2012).
Vendar ta sklep ne temelji samo na primerjalni analizi pravno zavezujočih zahtev, ki se uporabljajo za CNS v ZDA, ampak tudi na oceni učinkov teh zahtev in njihove primernosti za zmanjševanje tveganj, ki so jim lahko izpostavljeni klirinški člani in mesta trgovanja s sedežem v Uniji, in sicer na način, ki je enakovreden učinkom zahtev iz Uredbe (EU) št. 648/2012.
The legally binding requirements of the USA for CCPs authorised (the term used in the CFTC framework is ‘registration’) and supervised by the Commodity Futures Trading Commission (CFTC) are contained in the Commodity Exchange Act (‘the CEA’), as amended by Titles VII and VIII of the Dodd-Frank Wall Street Reform and Consumer Protection Act (‘the Dodd-Frank Act’), and the CFTC's regulations promulgated thereunder.
Pravno zavezujoče zahteve ZDA za CNS z dovoljenjem Komisije za trgovanje z blagovnimi terminskimi pogodbami (Commodity Futures Trading Commission (CFTC)) v tej državi (v okviru CFTC se uporablja izraz „registracija“) in pod njenim nadzorom vsebujejo Zakon o blagovni borzi (Commodity Exchange Act (CEA)), kot ga spreminjata naslova VII in VIII Zakona o Dodd-Frankovi reformi Wall Streeta in varstvu potrošnikov (Dodd-Frank Wall Street Reform and Consumer Protection Act) ter predpisi CFTC, objavljeni v skladu z njima.
The CFTC is the competent authority for the supervision of all derivative contracts that are not based on a single security (a bond or share), loan or a narrow based group or index of securities, and is responsible for authorising and regulating CCPs which provide clearing services for those derivative contracts (‘derivative clearing organizations’ or ‘DCOs’).
CFTC je pristojni organ za nadzor vseh pogodb na izvedene finančne instrumente, ki ne temeljijo na enem samem vrednostnem papirju (obveznici ali delnici), posojilu ali na ozki skupini ali indeksu vrednostnih papirjev, in je odgovorna za izdajo dovoljenj in urejanje CNS, ki opravljajo klirinške storitve za navedene pogodbe na izvedene finančne instrumente (v nadaljnjem besedilu: klirinške organizacije za izvedene finančne instrumente).
The derivative contracts falling under the competence of the CFTC therefore correspond to a subset of the derivative contracts covered by the provisions on CCPs set out in Regulation (EU) No 648/2012.
Pogodbe na izvedene finančne instrumente, ki spadajo v pristojnost CFTC, zato ustrezajo podvrsti pogodb na izvedene finančne instrumente, ki jih zajemajo določbe o CNS iz Uredbe (EU) št. 648/2012.
This Decision relates solely to the equivalence of the legal and supervisory arrangements for DCOs and not to the legal and supervisory arrangements for CCPs which provide clearing services for derivative contracts falling under the competence of the Securities and Exchange Commission (‘SEC’).
Ta sklep se nanaša samo na enakovrednost pravnih in nadzornih ureditev za klirinške organizacije za izvedene finančne instrumente in ne na pravne in nadzorne ureditve za CNS, ki zagotavljajo klirinške storitve za pogodbe na izvedene finančne instrumente, ki sodijo v pristojnost ameriške komisije za nadzor trga vrednostnih papirjev (Securities and Exchange Commission (SEC)).
Where a CCP is authorised as both a clearing agency under the jurisdiction of the SEC and a DCO, this Decision relates to those CCPs only in so far as they provide clearing services for derivative contracts falling under the CFTC's jurisdiction.
Če ima CNS dovoljenje kot klirinška agencija pod jurisdikcijo SEC in kot klirinška organizacija za izvedene finančne instrumente, se ta sklep na te CNS nanaša samo, če opravljajo klirinške storitve za pogodbe na izvedene finančne instrumente, ki sodijo v prisojnost CFTC.
The legally binding requirements applicable to CCPs authorised by the CFTC include high-level standards that are set out by the core principles for DCOs contained in section 5b(c)(2) of the CEA and Subparts A and B of Part 39 of the CFTC Regulations.
Pravno zavezujoče zahteve, ki se uporabljajo za CNS z dovoljenjem CFTC, vključujejo visoke standarde, ki jih določajo temeljna načela za klirinške organizacije za izvedene finančne instrumente iz oddelka 5b(c)(2) CEA in poddelov A in B dela 39 predpisov CFTC.
To be authorised by the CFTC, all CCPs must comply with those core principles.
Za pridobitev dovoljenja CFTC morajo vse CNS izpolnjevati navedena temeljna načela.
The core principles are complemented by specific enhanced risk management standards applicable to DCOs which have been designated by the Financial Stability Oversight Council of the USA as systemically important and for which the CFTC has been designated as the supervisory agency (‘SIDCOs’).
Temeljna načela dopolnjujejo posebni strožji standardi za upravljanje tveganj, ki veljajo za klirinške organizacije za izvedene finančne instrumente, ki jih je ameriški svet za nadzor finančne stabilnosti (Financial Stability Oversight Council) določil kot sistemsko pomembne in za katere je bila CFTC določena kot nadzorni organ (v nadaljnjem besedilu: sistemsko pomembne klirinške organizacije za izvedene finančne instrumente).
The enhanced risk management standards are set out in Subpart C of Part 39 of CFTC regulations (Regulations 39.30 to 39.42).
Strožji standardi za upravljanje tveganj so določeni v poddelu C dela 39 predpisov CFTC (predpisi 39.30 do 39.42).
The high-level standards and the specific enhanced risk management standards for SIDCOs (together, the ‘primary rules’) are applicable to SIDCOs and to DCOs which have not been designated as SIDCOs but have voluntarily opted to be legally bound by those specific risk management standards (‘opt-in DCOs’).
Visoki standardi in posebni strožji standardi za upravljanje tveganj za sistemsko pomembne klirinške organizacije za izvedene finančne instrumente (skupaj: osnovna pravila) se uporabljajo za sistemsko pomembne klirinške organizacije za izvedene finančne instrumente in klirinške organizacije za izvedene finančne instrumente, ki niso določene kot sistemsko pomembne klirinške organizacije za izvedene finančne instrumente, vendar so se prostovoljno odločile, da jih navedeni posebni standardi za upravljanje tveganj pravno zavezujejo (v nadaljnjem besedilu: prostovoljno vključene klirinške organizacije za izvedene finančne instrumente).
Those primary rules comprise the first tier of the legally binding requirements applicable to DCOs.
Ta osnovna pravila so prva raven pravno zavezujočih zahtev, ki se uporabljajo za klirinške organizacije za izvedene finančne instrumente.
Pursuant to the primary rules, DCOs must adopt internal rules and procedures which must be approved by the CFTC.
V skladu z osnovnimi pravili morajo klirinške organizacije za izvedene finančne instrumente sprejeti notranja pravila in postopke, ki jih mora odobriti CFTC.
In respect of certain standards set out under the primary rules, the DCO's internal rules and procedures must provide prescriptive detail on the way in which the DCO will meet those standards.
Notranja pravila in postopki klirinških organizacij za izvedene finančne instrumente morajo glede določenih standardov, ki jih določajo osnovna pravila, določati preskriptivne podrobnosti o tem, kako bo klirinška organizacija za izvedene finančne instrumente izpolnjevala navedene standarde.
Moreover, those internal rules and procedures contain requirements which complement the ones prescribed by the primary rules.
Poleg tega navedena notranja pravila in postopki vsebujejo zahteve, ki dopolnjujejo tiste, ki jih predpisujejo osnovna pravila.
Once approved by the CFTC, the internal rules and procedures become legally binding on the DCO and form an integral part of the legal and supervisory arrangements with which those DCOs must comply.
Ko CFTC odobri notranja pravila in postopke, postanejo ti za klirinško organizacijo za izvedene finančne instrumente pravno zavezujoči in predstavljajo sestavni del pravnih in nadzornih ureditev, ki jih morajo izpolnjevati klirinške organizacije za izvedene finančne instrumente.
In the case of non-compliance with the primary rules or the DCO's internal rules and procedures, the CFTC has the power to sanction those DCOs, including by imposing penalties and suspension or revocation of the authorisation.
CFTC lahko v primeru neizpolnjevanja osnovnih pravil ali notranjih pravil in postopkov klirinške organizacije za izvedene finančne instrumente te organizacije kaznuje, in sicer tudi z naložitvijo kazni in začasnim ali stalnim odvzemom dovoljenja.